Reference : Imaging apolipoprotein AI in vivo
Scientific journals : Article
Physical, chemical, mathematical & earth Sciences : Chemistry
http://hdl.handle.net/2268/102596
Imaging apolipoprotein AI in vivo
English
Sriram, Renuka [ > > ]
Lagerstedt, Jens [ > > ]
Petrlova, Jitka [ > > ]
Samardzic, Haris [ > > ]
Kreutzer, Ulrike [ > > ]
Xie, Hongtao [ > > ]
Kaysen, George [ > > ]
Desreux, Jean-François mailto [Université de Liège - ULg > Département de chimie (sciences) > Département de chimie (sciences) >]
Thonon, David mailto [Université de Liège - ULg > > Centre de recherches du cyclotron >]
Jacques, Vincent [ > > ]
Van Loan, M. [ > > ]
Rutledge, J. C. [ > > ]
Oda, M. N. [ > > ]
Voss, John [ > > ]
Jue, T. [ > > ]
2011
NMR in Biomedicine
Wiley
24
7
916-924
Yes (verified by ORBi)
International
0952-3480
Chichester
United Kingdom
[en] Coronary disease risk increases inversely with high-d. lipoprotein (HDL) level. The measurement of the biodistribution
and clearance of HDL in vivo, however, has posed a tech. challenge. This study presents an approach to the
development of a lipoprotein MRI agent by linking gadolinium methanethiosulfonate (Gd[MTS-ADO3A]) to a selective
cysteine mutation in position 55 of apo AI, the major protein of HDL. The contrast agent targets both liver and kidney,
the sites of HDL catabolism, whereas the std. MRI contrast agent, gadolinium-diethylenetriaminepentaacetic acidbismethylamide
(GdDTPA-BMA, gadodiamide), enhances only the kidney image. Using a modified apolipoprotein AI
to create an HDL contrast agent provides a new approach to investigate HDL biodistribution, metab. and regulation in
vivo.
http://hdl.handle.net/2268/102596
10.1002/nbm.1650

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
NMR Biomed_2011_24_916.pdfPublisher postprint1.55 MBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.